<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733460</url>
  </required_header>
  <id_info>
    <org_study_id>BFPET P-01</org_study_id>
    <nct_id>NCT00733460</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety, Biodistribution and Radiation Dosimetry of BFPET as a Potential Myocardial Perfusion Imaging (MPI) Agent for PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fluoropharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fluoropharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and dosimetry of BFPET™ will be evaluated in healthy volunteers and Coronary Artery
      Disease (CAD) patients , male or female and of age ranging between 20-80 years old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Procedures:

      Visit 1: Screening - Eligibility determination

      Visit 2 (within 14 days post screening): Injection of BFPET™ and PET Imaging

      Visit 3 (within 24-48 hours post dose): Follow-up Visit
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood pressure. Safety Biodistribution Radiation dosimetry</measure>
    <time_frame>pre-dose, post-dose 0, 1, 5, 15, 30, 60 and 90 minutes, 2 hours, 24-48 hours post-dose and 7 days post-dose.</time_frame>
    <description>Change in vital signs, physical examination, ECG measured within 14 days of screening, immediate pre-dose, post-dose and 24-48 hours post-dose.
Change in 12-lead Electrocardiogram measured within 14 days of screening, immediate pre-dose, post-dose and 24-48 hours post-dose.
Change in 24-hour Holter (initiated 2 hours pre-dose, continuous for 24 hours, time stop recorded.
Change in dosimetry sampling (blood and urine)blood measured at time 0 (immediately following injection), 1,5, 15, 30, 60, 90 minutes.
Adverse event assessment immediate post dose, 24-48 hours and 7 days post-dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance characteristics of BFPET as a PET tracer for myocardial imaging.</measure>
    <time_frame>30, 60, 120, and 240 seconds.</time_frame>
    <description>Whole body imaging measures radiation dosimetry at rest and under pharmacologic stress</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>BF-PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BFPET</intervention_name>
    <arm_group_label>BF-PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        NORMAL HEALTHY VOLUNTEERS Inclusion Criteria

          1. Subject must provide written informed consent prior to any study related procedures;

          2. Subject must be ≥ 20 and ≤ 80 years of age;

          3. Subject must have a serum creatinine within the investigational site's normal range.

          4. Subject must have liver function tests &lt; 1.5 times the investigational site's normal
             range.

          5. Subject must have a hematocrit level within 5% of the investigational site's normal
             range.

        Exclusion Criteria:

          1. Any clinically significant acute or unstable physical or psychological disease based
             on medical history or screening physical examination;

          2. Any clinically significant abnormality in the screening laboratory tests or ECG;

          3. Any exposure to any investigational drugs within four (4) weeks prior to Visit 1;

          4. Any exposure to investigational radiopharmaceuticals within four (4) weeks prior to
             the date of Visit 1;

          5. Any new prescription medications within four (4) weeks of Visit 1;

          6. Subject has a Positive (+) Serum Pregnancy Test, or the possibility of pregnancy
             cannot be ruled out prior to dosing or is breast-feeding. There are standard pregnancy
             procedures for use of radiopharmaceuticals in research at MGH.

          7. Subject has experienced any allergic reaction to similar radiofluorinated compounds or
             agents.

        CORONARY ARTERY DISEASE (CAD) SUBJECTS

        Inclusion Criteria:

          1. Subjects must provide written informed consent prior to any study related procedures;

          2. Subjects must be ≥ 20 and ≤ 80 years of age;

          3. Subjects must have history of CAD documented by an abnormal stress myocardial
             perfusion imaging (MPI) study and cardiac catheterization within 6 months of the BFPET
             studyExclusion Criteria

        Exclusion Criteria:

          1. Subject has a Positive (+) Serum and/or Urine Pregnancy Test or is lactating, or the
             possibility of pregnancy cannot be ruled out prior to dosing;

          2. Any clinically significant acute or unstable physical or psychological disease judged
             by the investigators based on medical history or screening physical examination;

          3. Coronary artery bypass graft (CABG) within 6 months;

          4. Percutaneous coronary intervention (PCI), with stent placement within six months;

          5. Blood pressure over 180/100;

          6. Acute changes in ECG;

          7. Recent (within 3 months) cardiac arrest, unstable angina, myocardial infarction,
             cerebro-vascular accident (CVA), any general anesthesia procedure, any surgical
             procedures;

          8. Any implanted pacemaker or defibrillator use within the last three months;

          9. Inability to remain in camera for approximately 60 minutes (Smokers and COPD are
             included as long as they can breath in PET camera and not taking O2 through nasal
             canula);

         10. History of Diabetes Mellitus;

         11. Serum creatinine &gt; 2 mg/dL;

         12. All cancer patients;

         13. Body Mass Index (BMI) is over 35;

         14. Any exposure to any investigational drugs or medical device within four (4) weeks
             prior to imaging study;

         15. Any exposure to radiopharmaceuticals within four (4) weeks prior to the date of
             imaging study;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Gewirtz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fluoropharma.com</url>
    <description>Click here for more information on BFPET P-01</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2008</study_first_posted>
  <last_update_submitted>June 6, 2013</last_update_submitted>
  <last_update_submitted_qc>June 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BFPET</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Myocardial Perfusion Imaging</keyword>
  <keyword>Radiation Dosimetry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

